· Investment Strategies · Updated
Birmingham AL Startups and VC Firms in 2026: Healthcare Density, Real Companies, Real Capital
Birmingham, Alabama’s venture map in 2026 — Shipt’s $550M Target exit, Acclinate and ArcheHealth raises, UAB spinouts, and the local funds that write first checks.
Editorial team
Birmingham, Alabama is not a coastal venture capital market. It is a healthcare-services city with hospital systems, UAB research, a Blue Cross Blue Shield of Alabama headquarters, and a downtown incubator campus at Innovation Depot. That buyer density is the point: software and life-science companies can prove product in Alabama even when Series A capital still comes from elsewhere.
This guide covers the companies and investors we actually profile — not a padded “top 50” list.
City hub: Birmingham Al · All cities: Cities · Fund directory: Directory
What Birmingham is (and is not)
| Birmingham is… | Birmingham is not… |
|---|---|
| A Southeast healthcare and life-sciences build site (UAB, large systems, BCBSAL) | A dense multi-stage VC HQ market like Atlanta or Boston |
| Home to real exits (Shipt → Target) and active digital-health raises | A place where “local Series B benches” replace national capital |
| Alabama only in our data | Birmingham, UK |
Startups we cover in Birmingham
| Company | What they do | Stage / status | Notable capital | Profile |
|---|---|---|---|---|
| Shipt | Same-day grocery / retail delivery marketplace | Acquired (Target, Dec 2017, $550M) | Greycroft and others pre-exit | Shipt |
| Acclinate | Clinical-trial diversity via NOWINCLUDED + AI | Series A ($7M, May 2024) | Cencora Ventures (lead); 450 Ventures at seed | Acclinate |
| ArcheHealth | AI ops / true cost-of-care for hospitals | Seed ($6.7M, Jun 2025) | LRVHealth, Martin Ventures, Texas Health Resources | Archehealth |
| Dialytix | UAB spinout “Kidney Cloud” for dialysis / kidney ops | Early / Prosper-backed | Prosper HealthTech | Dialytix |
| Revella Health | AI + clinical ops for Medicare Advantage Stars / risk | Early (Prosper relocator) | Prosper HealthTech | Revella Health |
| TIXiMED | Oral TXNIP inhibitor for Type 1 diabetes (UAB science) | Clinical-stage | Helmsley $2.65M PRI (Dec 2024); First Avenue ecosystem | Tiximed |
Why these names matter
Shipt is still the proof point outsiders ask for. Bill Smith’s Birmingham-founded marketplace sold to Target for $550M cash in December 2017 and kept Alabama roots in the corporate story. If you are building a consumer or logistics company here, that exit is the comps slide.
Acclinate is the clearest active Birmingham digital-health raise in our set: a $7M Series A (May 2024) led by Cencora Ventures, with Labcorp and Latimer participating, after seed capital that included 450 Ventures. The product thesis — community trust (NOWINCLUDED) plus AI for trial diversity — maps to FDA and sponsor pressure, not a vague “health equity” slogan.
ArcheHealth closed a $6.7M seed in June 2025 with hospital-system investors (Texas Health Resources alongside LRVHealth and Martin Ventures). That is a hospital cost / ops story — adjacent to revenue-cycle software without being classic billing RCM.
Dialytix and TIXiMED show the UAB path: kidney-care data ops versus oral Type 1 diabetes therapy. Different asset classes, same pattern — Birmingham science and clinical adjacency before national syndicate depth.
Revella Health is the Prosper HealthTech “relocate and stay” pattern: a payer / Stars / risk wedge that moved HQ to Birmingham after the accelerator.
Local investors (Birmingham HQ or program)
| Firm | Role | Stages | Profile |
|---|---|---|---|
| First Avenue Ventures | Life sciences + Opportunity Fund seed | Pre-seed – Series A | First Avenue Ventures |
| 450 Ventures | BCBS Alabama corporate venture | Seed – growth participation | 450 Ventures |
| Measured Capital | Care, workforce, financial access | Pre-seed – Series A | Measured Capital |
| Prosper HealthTech Accelerator | gener8tor healthtech program in Birmingham | Pre-seed / seed | Prosper Healthtech Accelerator |
| Bronze Valley | CDFI / investment accelerator | Pre-seed / seed | Bronze Valley |
| Alabama Futures Fund | $25M Alabama seed fund (Fund I; not accepting new submissions) | Seed (historical) | Alabama Futures Fund |
How to read this table: First Avenue and Prosper are the most practical first-money paths for healthcare founders. 450 Ventures matters when your product helps a regional payer’s members or medical economics. Alabama Futures Fund is listed for honesty — Fund I capital is largely deployed / closed to new pitches.
Innovation Depot (Voltage, Boost, workspace) remains the physical hub downtown. It is an incubator, not a classic VC fund in our directory — founders still use it for formation, talent, and intros.
National capital Birmingham founders still need
Local funds rarely replace a coastal or specialist Series A. When your round needs digital-health or multi-stage partners, these directory firms are the usual shortlist by thesis, not geography:
| Firm | Why Birmingham founders care | Profile |
|---|---|---|
| Define Ventures | Digital health / health-system software specialist | Define Ventures |
| F-Prime Capital | Healthtech and life-sciences–adjacent | F Prime Capital |
| Bessemer Venture Partners | Cloud/SaaS + healthcare roadmaps | Bessemer Venture Partners |
| General Catalyst | Multi-stage health + enterprise | General Catalyst |
Local seed vs national Series A — what differs
| Local Birmingham capital | National / coastal capital | |
|---|---|---|
| Best for | First checks, UAB spinouts, Prosper relocators, payer pilots | Series A+ when metrics or science milestones clear diligence |
| Typical instruments | Accelerator equity, Opportunity Fund checks, CVC | Priced rounds led by specialist or multi-stage GPs |
| What they underwrite | Buyer access in Alabama + team | Category, GTM, and ownership math |
| Mistake to avoid | Waiting for a Birmingham multi-stage HQ that does not exist | Pitching coastal firms with zero local customer proof |
Worked example (illustrative)
Setup: A Birmingham RCM / care-ops startup closes a $150k Prosper or Bronze Valley–style first check and lands two hospital pilot contracts.
Move: Eighteen months later ARR hits ~$1.2M with a named health-system logo; they raise a $8–12M Series A from a national digital-health firm (e.g. Define / F-Prime class).
Punch: The Alabama pilots were the diligence artifact — not a local lead GP. Treat local capital as runway and proof, not as your Series A syndicate.
When Birmingham is the wrong capital market
- You need a growth-equity lead tomorrow and refuse to leave Alabama for meetings — growth GPs still sit elsewhere.
- Your product has no healthcare or enterprise buyer in the metro and you expected “ecosystem gravity” alone to invent demand.
- You treat Alabama Futures Fund as open for new Seed I applications — it is not.
- You invent peer comps that are not Birmingham-HQ (e.g. Atlanta Patientory) to pad a local density slide.
How to use this page
- Read company pages: Acclinate, ArcheHealth, Shipt, Dialytix, TIXiMED, Revella.
- Shortlist local funds: First Avenue, 450 Ventures, Prosper, Measured, Bronze Valley.
- For Series A+, add national rows above from Directory.
- Track live matches on Birmingham Al. Compare Southeast depth via Atlanta Southeast VC firms 2026.
Related reading
Sources
- Company and fund profiles linked above (Venture Capital Tracker JSON)
- Target / Shipt acquisition coverage (Dec 2017, $550M)
- Acclinate Series A announcements (May 2024, $7M)
- ArcheHealth seed PR (Jun 2025, $6.7M)
- TIXiMED Helmsley PRI (Dec 2024, $2.65M)
- Prosper HealthTech / gener8tor program materials; Innovation Depot program pages
- birmingham
- alabama
- city
- +3 more
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.